Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery
Year: 2017
Type: article
Abstract: Chemotherapy-resistant cancer stem cells (CSCs) are a major obstacle to the effective treatment of many forms of cancer. To overcome CSC chemo-resistance, we developed a novel system by conjugating a CSC-targeting EpCAM aptamer with doxorubicin (Apt-DOX) to eliminate CSCs. Incubation of Apt-DOX with colorectal cancer cells resulted in high concentration and prolonged retention of DOX in the nuclei. Treatment of tumour-bearing xenograft mice with Apt-DOX resulted in at least 3-fold more inhibition of tumour growth and longer survival as well as a 30-fold lower frequency of CSC and a prolonged longer tumourigenic latency compared with those receiving the same dose of free DOX. Our data demonstrate that a CSC-targeting aptamer is able to transform a conventional chemotherapeutic agent into a CSC-killer to overcome drug resistance in solid tumours.
Source: Theranostics
DOI: 10.7150/thno.20168
Institutions: Deakin University, Commonwealth Scientific and Industrial Research Organisation, Australian Centre for Disease Preparedness, Zhengzhou University, Murdoch University, UNSW Sydney, St George Hospital, Sichuan University, Huaqiao University, Shaanxi Normal University, Shanghai Jiao Tong University, Shanghai Sixth People's Hospital
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $1,671
Award: G4055026852
OpenAlex ID: W2756575490
